Zimbabwe has declined a significant American health deal valued at $367m (£272m) over five years due to the United States' insistence on confidential biological samples.
The decision was revealed after a government memo from December was disclosed, indicating that President Emmerson Mnangagwa deemed the agreement was "lopsided".
A government representative later explained that the United States was demanding access to genetic material for scientific study and commercial gain but was not willing to share the benefits from any future treatments.
"We must now begin the difficult and regrettable task of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged further negotiations to reach a deal acceptable to all parties so the nation's critical HIV programme can continue.
Broader Background
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a court blocked a similar deal with the US after concerns were filed about the security of citizens' medical information.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government agreements to boost openness and responsibility.
As per reports, Sixteen African countries have to date signed similar agreements, constituting over $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration would have delivered significant advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to surrender its biological resources and data over an extended period, without any equivalent guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"In essence, our nation would supply the basic resources for medical research with no assurance that the final treatments would be accessible to our population if a new health crisis emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its push of bilateral deals were undermining structures previously set up through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This framework is designed to guarantee that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage further discussions with our US partners on how subsequent co-operation could be arranged in a manner that respects the sovereignty and interests of each country."
Health Experts Response
Medical experts expressed it acknowledged the government's concerns, but recommended that negotiations need to persist given that much of the nation's HIV programmes depended on foreign aid.
"If technical issues exist, such as those relating to data governance or implementation frameworks, these can frequently be addressed via detailed discussion and mutually agreed protections," it said.
The situation highlights the continuing debate between accepting vital foreign assistance and protecting a country's data in an ever more interconnected world.